204 related articles for article (PubMed ID: 9674857)
1. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia.
Passweg JR; Rowlings PA; Atkinson KA; Barrett AJ; Gale RP; Gratwohl A; Jacobsen N; Klein JP; Ljungman P; Russell JA; Schaefer UW; Sobocinski KA; Vossen JM; Zhang MJ; Horowitz MM
Bone Marrow Transplant; 1998 Jun; 21(12):1231-8. PubMed ID: 9674857
[TBL] [Abstract][Full Text] [Related]
2. Post-transplant infections: single center experience from the developing world.
Ullah K; Raza S; Ahmed P; Chaudhry QU; Satti TM; Ahmed S; Mirza SH; Akhtar F; Kamal K; Akhtar FM
Int J Infect Dis; 2008 Mar; 12(2):203-14. PubMed ID: 17920999
[TBL] [Abstract][Full Text] [Related]
3. Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin.
Bacigalupo A; Oneto R; Bruno B; Soracco M; Lamparelli T; Gualandi F; Occhini D; Raiola A; Mordini N; Berisso G; Bregante S; Dini G; Lombardi A; Lint MV; Brand R
Bone Marrow Transplant; 1999 Sep; 24(6):653-9. PubMed ID: 10490732
[TBL] [Abstract][Full Text] [Related]
4. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant.
Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
Bone Marrow Transplant; 2004 Oct; 34(8):721-7. PubMed ID: 15322568
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
Ringdén O; Labopin M; Frassoni F; Sanz G; Demeocq F; Prentice H; Cahn JY; Barbui T; Meloni G; Schaefer U; Reiffers J; Gorin N
Bone Marrow Transplant; 1999 Aug; 24(4):389-96. PubMed ID: 10467328
[TBL] [Abstract][Full Text] [Related]
6. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry.
Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE
J Clin Oncol; 2004 Dec; 22(24):4872-80. PubMed ID: 15520055
[TBL] [Abstract][Full Text] [Related]
7. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
[TBL] [Abstract][Full Text] [Related]
8. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
9. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
[TBL] [Abstract][Full Text] [Related]
10. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
Baker KS; Loberiza FR; Yu H; Cairo MS; Bolwell BJ; Bujan-Boza WA; Camitta BM; Garcia JJ; Ho WG; Liesveld JL; Maharaj D; Marks DI; Schultz KR; Wiernik P; Zander AR; Horowitz MM; Keating A; Weisdorf DJ
J Clin Oncol; 2005 Oct; 23(28):7032-42. PubMed ID: 16145067
[TBL] [Abstract][Full Text] [Related]
11. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program.
Kimura F; Sato K; Kobayashi S; Ikeda T; Sao H; Okamoto S; Miyamura K; Mori S; Akiyama H; Hirokawa M; Ohto H; Ashida H; Motoyoshi K;
Haematologica; 2008 Nov; 93(11):1686-93. PubMed ID: 18835834
[TBL] [Abstract][Full Text] [Related]
12. Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors.
Meijer E; Dekker AW; Rozenberg-Arska M; Weersink AJ; Verdonck LF
Clin Infect Dis; 2002 Sep; 35(6):703-12. PubMed ID: 12203168
[TBL] [Abstract][Full Text] [Related]
13. Unrelated donor marrow transplantation in childhood: a report from the Associazione Italiana Ematologia e Oncologia Pediatrica (AIEOP) and the Gruppo Italiano per il Trapianto Midollo Osseo (GITMO).
Dini G; Cancedda R; Giorgiani G; Porta F; Messina C; Uderzo C; Pession A; Fagioli F; La Nasa G; Arcese W; Pollichieni S; Zecca M; Lanino E; Mazzolari E; Cesaro S; Balduzzi A; Rondelli R; Vassallo E; Cappelli B; Locatelli F;
Haematologica; 2002 Aug; 87(8 Suppl):51-7. PubMed ID: 12412391
[TBL] [Abstract][Full Text] [Related]
14. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
16. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
17. ABO blood group barrier in allogeneic bone marrow transplantation revisited.
Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ;
Biol Blood Marrow Transplant; 2005 Dec; 11(12):1006-13. PubMed ID: 16338623
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
[TBL] [Abstract][Full Text] [Related]
19. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
